ArticleNeurocritical care2026
Effect of Desmopressin on Attaining Therapeutic Hypernatremia with Hypertonic Saline Continuous Infusion in Intracranial Hemorrhage.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet dysfunction in the setting of intracranial hemorrhage may potentiate worsening hemorrhage. Desmopressin may be used to treat platelet dysfunction in intracranial hemorrhage through von Willebrand factor release. Hypertonic saline is often used in this population to treat cerebral edema and elevated intracranial pressure. Free water reabsorption associated with desmopressin may attenuate the effect of hyperosmolar therapy. The effect of desmopressin on continuous infusion 3% sodium chloride (3%) when targeting a specific sodium goal has not been definitively elucidated. We hypothesize that a lower proportion of patients treated with desmopressin will have achieved a serum sodium of ≥ 150 mEq/L at 48 h versus those that did not receive desmopressin.
methodsThis is a retrospective cohort study at a level-1 trauma center and quaternary care center that included patients who received 3% infusions for at least 48 h following admission in the setting of intracranial hemorrhage of varying etiologies. The primary end point is the proportion of patients reaching a serum sodium of ≥ 150 mEq/L within 48 h of 3% initiation. To account for confounding variables, a logistic regression adjusted analysis was also performed to evaluate the primary end point.
resultsA total of 127 patients were included in this study; 75 were not treated with desmopressin, and 52 were treated with desmopressin. There was no significant difference noted in the attainment of serum sodium of 150 mEq/L within 48 h of 3% therapy in the control versus desmopressin group (47 [62.7%] vs. 34 [65.4%]; P = 0.7540). Adjusted logistic regression evaluating the effect of DDAVP on sodium goal attainment did not reach statistical significance (odds ratio 1.59 [95% confidence interval 0.56-4.52], P = 0.3851).
conclusionsDesmopressin does not appear to affect the ability to attain a therapeutic hypernatremia goal of ≥ 150 mEq/L within 48 h when using continuous infusion hypertonic saline.
Indexed as
Identifiers
41565894What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.